Mutant TDP-43 Protein Model for Neurodegenerative Disease Research
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current models fail to fully reproduce the intracellular accumulation of phosphorylated TDP-43 observed in patient brains, limiting the understanding and development of therapeutic strategies for neurodegenerative diseases like ALS and FTLD.
Innovation Solution
A mutant TDP-43 protein is created by deleting the nuclear localization signal and substituting specific amino acids, which is expressed in cell and mouse models using an adeno-associated virus vector, resulting in phosphorylated intracellular aggregates that mimic the pathology seen in patient brains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type TDP-43 is expressed in cell models, then the protein is properly localized in the nucleus, but it does not form intracellular aggregates or reproduce the pathology observed in patient brains
Solution Approach 1:
The patent removes the nuclear localization signal (NLS) from the TDP-43 protein sequence, extracting the element that controls nuclear import. This causes the protein to be mislocalized to the cytoplasm, enabling aggregate formation and reproducing the pathological state observed in ALS and FTLD patient brains, thereby resolving the contradiction between proper localization and pathology reproduction.
Solution Approach 2:
The patent introduces specific amino acid mutations (F147L, F149L, F194L, F229L, F231L) at conserved phenylalanine positions in the RNA-binding domain. These parameter changes in the protein sequence disrupt RNA binding capability and promote cytoplasmic aggregation, transforming the protein from a normally localized nuclear protein to a pathologically aggregated cytoplasmic protein that reproduces disease features.
2Reliability
If TDP-43 mutations are introduced to promote aggregation, then intracellular aggregates form, but the model fails to reproduce phosphorylated TDP-43 accumulation specifically
Solution Approach 1:
The patent creates a simplified model system that copies the essential feature of phosphorylated TDP-43 accumulation without requiring complex mutation combinations. By using a single mutation (F147L/F149L) combined with NLS deletion, the model reproduces the key pathological feature of phosphorylated aggregate formation, avoiding the complexity of multiple simultaneous mutations while maintaining biological relevance.
3Adaptability or versatility
If existing TDP-43 models are used, then some aspects of protein expression are achieved, but they cannot serve as effective platforms for therapeutic drug screening
Solution Approach 1:
The patent creates a universal cell model system that simultaneously achieves multiple functions: (1) reproduces phosphorylated TDP-43 aggregate formation, (2) maintains cell viability and proliferation, (3) allows for drug screening applications, and (4) represents relevant disease mechanisms. This multi-functional model can be used for both basic research and therapeutic development, resolving the contradiction between model specificity and versatility.
Data Source
AI summary
A mutant TDP-43 protein, having a deletion of a nuclear localization signal sequence in the amino acid sequence of a wild-type TDP-43 protein, and also having any one of the following mutations (a) to (c) or a combination of these mutations:(a) a mutation, in which the 147th and 149th phenylalanines are substituted with leucines,(b) a mutation, in which the 194th phenylalanine is substituted with leucine, and(c) a mutation, in which the 229th and 231st phenylalanines are substituted with leucines.